BIOSYNEX INH. EO-10
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more
BIOSYNEX INH. EO-10 (0DL) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOSYNEX INH. EO-10 (0DL) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOSYNEX INH. EO-10 - Net Assets Trend (None–None)
This chart illustrates how BIOSYNEX INH. EO-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOSYNEX INH. EO-10 (None–None)
The table below shows the annual net assets of BIOSYNEX INH. EO-10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOSYNEX INH. EO-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOSYNEX INH. EO-10 Competitors by Market Cap
The table below lists competitors of BIOSYNEX INH. EO-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Texchem Resources Bhd
KLSE:8702
|
$6.75 Million |
|
Queen's Road Capital Investment Ltd
PINK:BRSGF
|
$6.75 Million |
|
Sidiz Inc
KO:134790
|
$6.76 Million |
|
AroCell AB
ST:AROC
|
$6.76 Million |
|
Marine Petroleum Trust
NASDAQ:MARPS
|
$6.75 Million |
|
FlexQube AB (publ)
F:A1Y
|
$6.75 Million |
|
Artroniq Berhad
KLSE:0038
|
$6.75 Million |
|
A.F.P. Planvital S.A.
SN:PLANVITAL
|
$6.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOSYNEX INH. EO-10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOSYNEX INH. EO-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOSYNEX INH. EO-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOSYNEX INH. EO-10's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOSYNEX INH. EO-10 (0DL) | €- | N/A | N/A | $6.75 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.30 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $42.41 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.72 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $620.14 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.29 Million |